Search results
Added:
5 months ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients…
View more
Added:
5 months ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
View more
Added:
3 years ago
Hypertension remains a prevalent, major risk factor for cardiovascular disease (CVD), affecting over one-third of adults in the uS—nearly 74 million people.1 In the uS, elevated blood pressure (BP) contributes to 69% of first myocardial infarctions (MIs), 74% of cases of congestive heart failure (CHF), and 77% of first strokes.1 The total direct and indirect cost of CVD and stroke in the US for…
View more
Added:
3 years ago
Hypertension (HT) remains the most common preventable risk factor for cardiovascular (CV) morbidity and mortality. There are exciting new data about epidemiology, brachial blood pressure (BP), ambulatory blood pressure monitoring (ABPM) and pre-hypertension from large clinical trials.
Increasing Burden of Hypertension Worldwide
The incidence of HT is rising worldwide due to common environmental…
View more
Added:
6 months ago
What's hot at TCT 2023?
In this episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the late-breaking data presented at TCT 2023.
With their dynamic analysis, these anticipated trials are placed in context, highlighting the real-world implications tied to the data releases.
Top trials covered:
00:31 - 02:12: PARTNER 3 Low…
View more
Added:
3 years ago
Moderate-to-severe tricuspid regurgitation (TR) is estimated to affect more than 1.6 million people in the US. However, fewer than 8,000 tricuspid valve operations are performed each year.1,2 There is clearly an unmet need for a tricuspid valve (TV) intervention. There has been rapid development in the field of transcatheter aortic and mitral valve interventions and percutaneous management of…
View more
Added:
3 years ago
Hypertension is an important contributor to global morbidity and mortality and is a major burden on healthcare systems.1,2 More than 20% of the world’s population has high blood pressure when defined by conventional criteria: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.3,4 Even with therapeutic lifestyle and pharmacological measures, blood pressure remains poorly…
View more
Added:
3 years ago
Despite advances in diagnostic and treatment modalities, hypertension remains a prevalent medical condition, affecting over 26 % of the adult population, a number expected to rise to nearly 30 % by the year 2025.1 It is a major risk factor for cardiovascular disease morbidity and mortality, including stroke, heart failure, and renal disease.2,3 Numerous investigations have demonstrated the…
View more
Added:
2 months ago
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a disorder of the pulmonary circulation in which elevated pressure in the pulmonary vascular circuit, when severe, can lead to right heart failure and eventually cause death. The last three decades have seen significant advances in our understanding of this group of disorders and, with this understanding, the development of novel therapies to assist in…
View more
